Virus-based cancer vaccines are nowadays considered an interesting approach in the field of cancer immunotherapy, despite the observation that the majority of the immune responses they elicit are against the virus and not against the tumor. In contrast, targeting tumor associated antigens is effective, however the identification of these antigens remains challenging. Here, we describe ExtraCRAd, a multi-vaccination strategy focused on an oncolytic virus artificially wrapped with tumor cancer membranes carrying tumor antigens. We demonstrate that ExtraCRAd displays increased infectivity and oncolytic effect in vitro and in vivo. We show that this nanoparticle platform controls the growth of aggressive melanoma and lung tumors in vivo both in preventive and therapeutic setting, creating a highly specific anti-cancer immune response. In conclusion, ExtraCRAd might serve as the next generation of personalized cancer vaccines with enhanced features over standard vaccination regimens, representing an alternative way to target cancer.

Artificially cloaked viral nanovaccine for cancer immunotherapy / Fusciello, M.; Fontana, F.; Tahtinen, S.; Capasso, C.; Feola, S.; Martins, B.; Chiaro, J.; Peltonen, K.; Ylosmaki, L.; Ylosmaki, E.; Hamdan, F.; Kari, O. K.; Ndika, J.; Alenius, H.; Urtti, A.; Hirvonen, J. T.; Santos, H. A.; Cerullo, V.. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - 10:1(2019), p. 5747. [10.1038/s41467-019-13744-8]

Artificially cloaked viral nanovaccine for cancer immunotherapy

Feola S.;Cerullo V.
Ultimo
Supervision
2019

Abstract

Virus-based cancer vaccines are nowadays considered an interesting approach in the field of cancer immunotherapy, despite the observation that the majority of the immune responses they elicit are against the virus and not against the tumor. In contrast, targeting tumor associated antigens is effective, however the identification of these antigens remains challenging. Here, we describe ExtraCRAd, a multi-vaccination strategy focused on an oncolytic virus artificially wrapped with tumor cancer membranes carrying tumor antigens. We demonstrate that ExtraCRAd displays increased infectivity and oncolytic effect in vitro and in vivo. We show that this nanoparticle platform controls the growth of aggressive melanoma and lung tumors in vivo both in preventive and therapeutic setting, creating a highly specific anti-cancer immune response. In conclusion, ExtraCRAd might serve as the next generation of personalized cancer vaccines with enhanced features over standard vaccination regimens, representing an alternative way to target cancer.
2019
Artificially cloaked viral nanovaccine for cancer immunotherapy / Fusciello, M.; Fontana, F.; Tahtinen, S.; Capasso, C.; Feola, S.; Martins, B.; Chiaro, J.; Peltonen, K.; Ylosmaki, L.; Ylosmaki, E.; Hamdan, F.; Kari, O. K.; Ndika, J.; Alenius, H.; Urtti, A.; Hirvonen, J. T.; Santos, H. A.; Cerullo, V.. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - 10:1(2019), p. 5747. [10.1038/s41467-019-13744-8]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/838544
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 82
  • ???jsp.display-item.citation.isi??? 75
social impact